Subscribe
Subscribe

MY AMERICAN SCIENTIST: Login is temporarily disabled for maintenance.

SEARCH
 
Logo IMG
HOME > MULTIMEDIA > Multimedia Detail

SCIENCE IN THE NEWS DAILY

Melanoma Drug Combo Packs a One-Two Punch

from ScienceNOW Daily News

Drug resistance is the bane of cancer researchers and patients. But early results from a new clinical trial suggest a way to get around a tumor's defenses. By combining high doses of two new drugs against advanced melanoma, scientists were able to delay for months the cancer's ability to evade the therapy aimed at a tumor's molecular weak spot.

The trial is testing a so-called BRAF inhibitor, a widely heralded new type of melanoma drug. It targets a growth-spurring protein, BRAF, encoded by a mutation in the BRAF gene that occurs in about half of melanoma patients. Although the drug extends patients' lives--on average they live 14 to 15 months, versus 8 months on conventional therapy--their tumors eventually develop resistance and begin growing again. Often the tumors restore the BRAF growth pathway by turning on a downstream protein called MEK, suggesting that combining a MEK inhibitor and a BRAF inhibitor could stave off cancer growth longer.

That strategy now shows signs of working, according to data released today in advance of the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, from 1-5 June. In 77 patients who took a BRAF inhibitor and a MEK inhibitor made by GlaxoSmithKline, the drugs shrank tumors or delayed growth by 7.4 months on average--no longer than has been reported for the BRAF inhibitor alone. But the results were more encouraging for 24 patients who received the highest doses of the two drugs. Their tumors became stable or shrank and did not resume growing for 10.8 months on average.

Read more...


comments powered by Disqus
 

Connect With Us:

Facebook Icon Sm Twitter Icon Google+ Icon Pinterest Icon RSS Feed Instagram Icon

Latest Multimedia

Flooded Sign

PODCAST & VIDEO: Engineering Around Extreme Events

Extreme events, such as super floods and hurricanes, are becoming more common, so civil engineers are trying to adapt civil infrastructure such as bridges to these unpredictable and sometimes devastating meteorological events. Engineer Ana Barros discusses how engineering can prepare us for extreme weather events, but also how changing climate and population conditions can affect the ability of infrastructure to hold up over time.

To view all multimedia content, click "Latest Multimedia."



RSS Feed Subscription

Receive notification when new content is posted from the entire website, or choose from the customized feeds available.


EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Three Doctors Charged in Armstrong Doping Case

Science In The News Daily: Antibody Cocktail Cures Monkeys of Ebola

Science In The News Daily: Diesel Exhausts Do Cause Cancer, Says WHO

Subscribe to American Scientist